Our Pipeline

In addition to our FDA-approved treatment for Duchenne muscular dystrophy, we are developing a variety of drug candidates based on our proprietary RNA-based technology and unique phosphorodiamidate morpholino oligomer – or PMO – chemistry.

 
 
 
 

Our therapeutic development programs include additional clinical candidates for Duchenne muscular dystrophy and infections of public health significance, including influenza and multi-drug resistant bacterial infections.

  • PROGRAM
  • DISCOVERY
  • preclinical
  • PHASE 1
  • PHASE 2
  • PHASE 3
 

RARE DISEASES

  • DMD EXON 51 (ETEPLIRSEN / AVI-4658)
  • DMD EXON 53 (SRP-4053)
  • DMD EXON 45 (SRP-4045)
  • DMD EXON 44
  • DMD EXON 52 (SRP-4052)
  • DMD EXON 50
  • DMD EXON 43
  • DMD EXON 55
  • DMD EXON 8
  • DMD EXON 35
  • NON-DMD TARGETS
 

INFECTIOUS DISEASES

  • AVI-7288
    MARBURG VIRUS
  • AVI-7537
    EBOLA VIRUS
  • AVI-7100
    INFLUENZA
  • VIRAL PMO-X
    DENGUE
  • BACTERIAL PPMO
    TB
  • UNDISCLOSED TARGETS